These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 36263134)

  • 1. The role of immune checkpoints in cardiovascular disease.
    Yousif LI; Tanja AA; de Boer RA; Teske AJ; Meijers WC
    Front Pharmacol; 2022; 13():989431. PubMed ID: 36263134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitors associated cardiovascular immune-related adverse events.
    Jo W; Won T; Daoud A; Čiháková D
    Front Immunol; 2024; 15():1340373. PubMed ID: 38375475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T cell checkpoint regulators in the heart.
    Grabie N; Lichtman AH; Padera R
    Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune-related adverse events in various organs caused by immune checkpoint inhibitors.
    Okiyama N; Tanaka R
    Allergol Int; 2022 Apr; 71(2):169-178. PubMed ID: 35101349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events.
    Poto R; Troiani T; Criscuolo G; Marone G; Ciardiello F; Tocchetti CG; Varricchi G
    Front Immunol; 2022; 13():804597. PubMed ID: 35432346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiotoxicity of immune checkpoint inhibitors.
    Varricchi G; Galdiero MR; Marone G; Criscuolo G; Triassi M; Bonaduce D; Marone G; Tocchetti CG
    ESMO Open; 2017; 2(4):e000247. PubMed ID: 29104763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac Complications in Immune Checkpoint Inhibition Therapy.
    Tajiri K; Ieda M
    Front Cardiovasc Med; 2019; 6():3. PubMed ID: 30729114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
    Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
    Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atherosclerosis With Immune Checkpoint Inhibitor Therapy: Evidence, Diagnosis, and Management:
    Suero-Abreu GA; Zanni MV; Neilan TG
    JACC CardioOncol; 2022 Dec; 4(5):598-615. PubMed ID: 36636438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review.
    Cozma A; Sporis ND; Lazar AL; Buruiana A; Ganea AM; Malinescu TV; Berechet BM; Fodor A; Sitar-Taut AV; Vlad VC; Negrean V; Orasan OH
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitors-Associated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge.
    Frascaro F; Bianchi N; Sanguettoli F; Marchini F; Meossi S; Zanarelli L; Tonet E; Serenelli M; Guardigli G; Campo G; Calabrò L; Pavasini R
    J Clin Med; 2023 Dec; 12(24):. PubMed ID: 38137806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.
    D'Arrigo P; Tufano M; Rea A; Vigorito V; Novizio N; Russo S; Romano MF; Romano S
    Curr Med Chem; 2020; 27(15):2402-2448. PubMed ID: 30398102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint biology in health & disease: Immune checkpoint biology and autoimmunity in cancer patients.
    Van Mol P; Donders E; Lambrechts D; Wauters E
    Int Rev Cell Mol Biol; 2024; 382():181-206. PubMed ID: 38225103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical models of cardiotoxicity from immune checkpoint inhibitor therapy.
    Buehning F; Lerchner T; Vogel J; Hendgen-Cotta UB; Totzeck M; Rassaf T; Michel L
    Basic Res Cardiol; 2024 Jul; ():. PubMed ID: 39039301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors.
    Chennamadhavuni A; Abushahin L; Jin N; Presley CJ; Manne A
    Front Immunol; 2022; 13():779691. PubMed ID: 35558065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heart-Specific Immune Responses in an Animal Model of Autoimmune-Related Myocarditis Mitigated by an Immunoproteasome Inhibitor and Genetic Ablation.
    Bockstahler M; Fischer A; Goetzke CC; Neumaier HL; Sauter M; Kespohl M; Müller AM; Meckes C; Salbach C; Schenk M; Heuser A; Landmesser U; Weiner J; Meder B; Lehmann L; Kratzer A; Klingel K; Katus HA; Kaya Z; Beling A
    Circulation; 2020 Jun; 141(23):1885-1902. PubMed ID: 32160764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies.
    Ronen D; Bsoul A; Lotem M; Abedat S; Yarkoni M; Amir O; Asleh R
    Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor immune checkpoints and their associated inhibitors.
    Gao Z; Ling X; Shi C; Wang Y; Lin A
    J Zhejiang Univ Sci B; 2022 Oct; 23(10):823-843. PubMed ID: 36226537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions:
    Tan S; Day D; Nicholls SJ; Segelov E
    JACC CardioOncol; 2022 Dec; 4(5):579-597. PubMed ID: 36636451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
    Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
    J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.